Buy or sell Freenome stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Freenome Stock

Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome

About Freenome Stock

Headquartered in South San Francisco, Freenome is a health technology company developing accurate, accessible and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. Freenome aims to reinvent disease management through systematized early detection and intervention. Since launching in 2014, the company has raised more than $70 million from leading technology and healthcare investors.

Funding History

June 2016$5.5M
March 2017$65.0M
August 2017$7.0M


Co-Founder, COO

Riley Ennis

Data Scientist

Kate Niehaus

Co-Founder, CTO

Michael Otte

Chief Bioinformatician

Adam Drake

CEO, Co-Founder

Gabriel Otte


Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Freenome or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 210K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: